This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Gastrointestinal Diseases  • Glaucoma  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

George C. Papachristou, BS; Robert Ritch, MD; Jeffrey M. Liebmann, MD

Arch Ophthalmol. 2008;126(5):732-733.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Prostaglandin analogues are the first choice of treatment for glaucoma in part because of their limited systemic adverse effects. Only the Travatan (Alcon Laboratories Inc, Fort Worth, Texas) (travoprost ophthalmic solution, 0.004%) label lists gastrointestinal adverse effects, noting dyspepsia and gastrointestinal disorders at a rate of 1% to 5%.¹ Neither Xalatan (Pfizer Inc, New York, New York) (latanoprost ophthalmic solution, 0.005% [50 µg/mL]) nor Lumigan (Allergan Inc, Irvine, California) (bimatoprost ophthalmic solution, 0.03% [0.3 mg/mL]) lists any gastrointestinal adverse effects on their labels.

Prostaglandin analogues have a favorable systemic adverse effect profile, with rare reports of discontinuation of treatment secondary to adverse events.² We describe 3 patients with transient gastrointestinal adverse effects after prostaglandin analogue use. The adverse effects in all 3 patients were confirmed by means of unmasked challenge-rechallenge tests, and all 3 patients were tested with at . . . [Full Text of this Article]

Report of Cases

Case 1

Case 2

Case 3

Comment

AUTHOR INFORMATION